Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DFN-02 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DFN-02 | EXPERIMENTAL | DFN-02 to be taken during migraine attack |
| Name | Type | Description |
|---|---|---|
| DFN-02 | DRUG | Active Experimental Drug |
Inclusion Criteria: 1. Patients with a history of acute migraine (using International Classification of Headache Disorders \[ICHD\] criteria, second edition); 2. Patients who, in the opinion of the investigator, are willing and able to: * Return to the study site within 72 hours of the first us...
DFN-02 is an investigational small molecule being developed for the treatment of acute migraine. It is currently in Phase 3 clinical development, though the specific mechanism of action has not been disclosed. The drug is intended to provide relief for patients experiencing acute migraine attacks.
DFN-02 is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker symbol RDY. The company is conducting clinical trials to evaluate the safety and efficacy of DFN-02 for the treatment of acute migraine.
DFN-02 is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial for DFN-02 has been completed, and the drug is being evaluated for its safety and tolerability in patients with acute migraine.
DFN-02 has been studied in one completed Phase 3 clinical trial with the identifier NCT02279082. This open-label safety study enrolled 167 patients with acute migraine in the United States. The trial was not randomized or double-blinded and had no control group, focusing on safety outcomes.
DFN-02 is not FDA approved. It is an investigational drug currently in Phase 3 clinical development. The completed Phase 3 trial, NCT02279082, was an open-label safety study, and the drug has not yet received regulatory approval for the treatment of acute migraine.